{"name":"Athersys","slug":"athersys","ticker":"ATHX","exchange":"NASDAQ (Delisted)","domain":"athersys.com","description":"Athersys is a biopharmaceutical company focused on developing novel cell therapies for the treatment of various diseases. The company's lead product, MultiStem, is a cell therapy that has shown promise in treating conditions such as ischemic stroke, heart failure, and inflammatory bowel disease. Athersys has a strong pipeline of products in various stages of development, with a focus on regenerative medicine. The company is well-positioned to capitalize on the growing demand for cell therapies in the biotech industry.","hq":"Cleveland, OH","founded":0,"employees":"","ceo":"Daniel Camardo (post-restructuring)","sector":"Cell Therapy Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$8M","metrics":{"revenue":5325000,"revenueGrowth":-3.4,"grossMargin":0,"rdSpend":65031000,"netIncome":-72534000,"cash":27731000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"MultiStem patent cliff ($0.0B at risk)","drug":"MultiStem","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Athersys Announces FDA Clearance of IND for MultiStem Cell Therapy","summary":"Athersys announced that the FDA has cleared the Investigational New Drug (IND) application for its MultiStem cell therapy, enabling the company to initiate clinical trials in the United States.","drugName":"MultiStem","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Athersys Reports Third Quarter 2023 Financial Results","summary":"Athersys reported its third quarter 2023 financial results, with a net loss of $4.4 million and a cash balance of $34.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Athersys Enters into Collaboration Agreement with Pfizer","summary":"Athersys announced a collaboration agreement with Pfizer to develop and commercialize its MultiStem cell therapy for the treatment of ischemic stroke.","drugName":"MultiStem","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOZ3hXekQxbXZIaDJ5Qlg1Y2xyZk1DWl85MkdNbDVMczZWSGpEV3Nlckw2THB5MzNNOGVqRVVmajY0TVJoWTExQU4wdGplQ3pqdXVUU3hZOHRjQVl3bnBzdWhydGN0NW1aLTF1MkFTRnp3SGc5RkhLalpTaVFZdTNTWC1aWUhuM1c2bEUwVC1wdWtfRjZ4RWtmajVvcjJhNG5VTGVfXzdIWkt1b3FiWFk0NDdmb3VmRkJjRldtaA?oc=5","date":"2026-04-06","type":"pipeline","source":"Defense World","summary":"Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World","headline":"Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPMUllcThnODN2Uk5vMVFUVHFxZzJBNWVSek96Sl9ESjVDYTlzOUJnNVBxVzBDbmljZmdZcVN3MVM3QjE3Y3o5dXJrZkxrSXVNYlR5d1NQYzhpUENWcmpEZWk2eDBKMG00ckI3NnoxS3kxX29YQVduckxfSHZNRnhCYUVycXpMNG91LXlSdkxNQlpwbGU5X0F1MzBUQm1zWVFzQmRUZE0yODVRM29mUG1TVmdyLVBHbmk4UEtGVkpLRFJfa2M?oc=5","date":"2026-04-03","type":"regulatory","source":"National Today","summary":"Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today","headline":"Athersys and Turn Therapeutics Battle for Biotech Supremacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPY3hOcWotUDlRdTZYSU5HVmFaelhwTWU3N2M4SGYxbE9kVkJlaHoxQ2JjTEhkbmFLUDhRMWZXZUlCREdneFJCMjZTUjVCNTJCSFJETEhUWVF5Tk5yVUJxdXZoaTBEYVBzdFZpSGI4bFBWamtPbWZkQTVxdGdvdlRKTG1fdGZmSWdsZVpMZXFabm40WWdOVjJsQXpkcm5UQlVXbW5tVE9hUmx5YjRiYTRhcVh3NA?oc=5","date":"2026-03-28","type":"pipeline","source":"Defense World","summary":"Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX) - Defense World","headline":"Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5oTGNHeXFiSzctQWtQU0lzcWdXZGdoV0NyeENLY1l4Q0FGQnlVUXRMS1Zsb1d2V2ZLcWlQSnNENTlNandXNTNjLTh1cklqNTd4T1Fr?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ATHX Stock Price, News & Analysis - Stock Titan","headline":"ATHX Stock Price, News & Analysis","sentiment":"neutral"},{"date":"2024-04-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-12-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-16","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOakZGT0liN1E5R3E5dm01QklOejVNYjVpLVR6M0hyQlF1X1oyWUc3MVZmS251dWVoMFZqb2dGeC10MWR0WllxWnM5RGtkdkxaai02MHpPdW9PME41cVQ0MnRLQnYyT2haYzZieEdYV2l6Sm10QzljemRHc25LZFE1R3dYQnFlVTBwTGcyQWdmdkR1ZDR1MmlGRVV5LVB6ZDFadE9CRzFNTUFJYzRubmJBcHRhYjJ2MDN2TVJpeVdLdVFPTHA1WnZSQUFMUHdaeTBtZVd0cVJVdF9vTEdHQXc?oc=5","date":"2021-08-05","type":"deal","source":"Business Wire","summary":"Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership - Business Wire","headline":"Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1iS1hmQk1tQ01HNkJOVkptZng1bGwxOV8taENsOGx5Q0VfYUtnTFdZdVFQSEExaV81eGxfb0ZFWVQ5LXJKR0FIRlNQQ1gtZjVUYmJWZnlCeXdXdw?oc=5","date":"2016-08-15","type":"pipeline","source":"MarketBeat","summary":"Athersys (ATHX) Stock Price, News & Analysis - MarketBeat","headline":"Athersys (ATHX) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"MultiStem","drugSlug":"multistem","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Mesoblast","Pluristem","BioTime"],"therapeuticFocus":["Regenerative Medicine","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":5325000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":5325000,"period":"2022-12-31"},{"value":5514000,"period":"2021-12-31"},{"value":5514000,"period":"2021-12-31"},{"value":722000,"period":"2021-12-31"},{"value":4792000,"period":"2021-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":65031000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-72534000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":27731000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}